Clinical Research Directory
Browse clinical research sites, groups, and studies.
Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice
Sponsor: Sanofi
Summary
The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation and causal inference to estimate comparative treatment effects.
Official title: Reduction in Low-Density Lipoprotein Cholesterol With Alirocumab 150 mg as Compared With Inclisiran: Comparative Evaluation Via Target-Trial Emulation and G-Computation
Key Details
Gender
MALE
Age Range
18 Years - 65 Years
Study Type
OBSERVATIONAL
Enrollment
996
Start Date
2025-05-22
Completion Date
2026-06-30
Last Updated
2026-07-09
Healthy Volunteers
No
Conditions
Interventions
Alirocumab 150 mg
The study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.
Inclisiran
The study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.
Locations (1)
Sanofi
Bridgewater, New Jersey, United States